Where is the future of endometrial cancer therapy?

Annals of Oncology

Volumn 20, Issue 11, 2009, Pages 1757-1761

  McMeekin, D Scott ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOXORUBICIN; IFOSFAMIDE; IXABEPILONE; PACLITAXEL; TEMSIROLIMUS; TOPOTECAN;

CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DRUG EFFICACY; DRUG TOLERABILITY; EDITORIAL; ENDOMETRIUM CANCER; HEART DISEASE; HUMAN; HYPERTENSION; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; OVARY CANCER; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; SURVIVAL TIME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; COMBINED MODALITY THERAPY; ENDOMETRIAL NEOPLASMS; FEMALE; HUMANS;

EID: 71049153208     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp493     Document Type: Editorial

References (28)

1. Randall M, Filiaci V, Muss H et al. Randomized phase III trial of WART versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: A GOG study. J Clin Oncol 2006; 24: 36-44.
2. Homesley HD, Filiaci V, Gibbons S et al. A randomized phase III trial in advanced endometrial carcinoma of surgery and volume directed radiation followed by cisplatin and doxorubicin with or without paclitaxel: A GOG study. Gynecol Oncol 2009; 112: 543-552.
3. Sagae S, Udagawa Y, Susumu N et al. Randomized phase III trial of whole pelvic radiotherapy vs. cisplatin-based chemotherapy in patients with intermediate risk endometrial carcinoma. Gynecol Oncol 2008; 108: 226-233.
4. Maggi R, Lissoni A, Spina F et al. Adjuvant chemotherapy vs. radiotherapy in high-risk endometrial carcinoma: Results of a randomized trial. Br J Cancer 2006; 95: 266-271.
5. Hogberg T, Rosenberg P, Kristensen G et al. A randomized phase III study on adjuvant treatment with radiation +/- chemotherapy in early stage high-risk endometrial cancer (NSGO-EC-9501/EORTC 55991). J Clin Oncol 2007; 25 (Suppl): 18S (Abstr 5503).
6. Ang JE, Shah RN, Everard M et al. A feasibility study of sequential doublet chemotherapy, comprising carboplatin/doxorubicin and carboplatin/ paclitaxel for advanced endometrial adenocarcinoma and carcinosarcoma. Ann Oncol 2009; 20: 1787-1793.
7. Fleming G. Systemic chemotherapy for uterine carcinoma: Metastatic and adjuvant. J Clin Oncol 2007; 25: 2983-2990.
8. Humber CE, Tierney JF, Symonds RP et al. Chemotherapy for advanced, recurrent or metastatic endometrial cancer: A systematic review of the Cochrane collaboration. Ann Oncol 2007; 18: 409-420.
9. Thigpen JT, Buchsbaum HJ, Mangan C, Blessing J. Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group study. Cancer Treat Rep 1979; 63: 21-27.
10. Thigpen JT, Blessing JA, Homesley H et al. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 1989; 33: 68-70.
11. Thigpen JT, Brady MF, Homesley HD et al. Phase III trial of doxorubicin with or without cisplatin in advanced endometrial carcinoma: A GOG study. J Clin Oncol 2004; 22: 3902-3908.
12. Aapro MS, van Wijk FH, Bolis G et al. Doxorubicin and cisplatin in endometrial carcinoma: Definitive results of a randomized study (55872) by the EORTC Gynecologic Cancer Group. Ann Oncol 2003; 14: 441-448.
13. Homseley HD, Blessing JA, Sorosky J et al. Phase II evaluation of liposomal doxorubicin at 40 mg/m2 every 4 weeks in endometrial cancer: A GOG study. Gynecol Oncol 2005; 98: 294-298.
14. Muggia F, Blessing J, Sorosky J, Reid G. Phase II trial of pegylated liposomal doxorubicin in previously treated metastatic endometrial cancer: A Gynecologic Oncology Group study. J Clin Oncol 2002; 20: 2360-2364.
15. du Bois A, Pfister J, Burchardi N et al. Combination therapy with pegylated liposomal doxorubicin and carboplatin in gynecologic malignancies: A prospective phase II study of the AGO-OVAR and AGO-K-Ut. Gynecol Oncol 2007; 107: 518-525.
16. Pignata S, Scambia G, Pisano C et al. A multicentre phase II study of carboplatin plus pegylated liposomal doxorubicin as first-line chemotherapy for patients with advanced or recurrent endometrial carcinoma: The END-1 study of the MITO. Br J Cancer 2007; 96: 1639-1643.
17. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: A GOG study. Gynecol Oncol 1996; 62: 278-281.
18. Lincoln S, Blessing JA, Lee RB, Rocereto TF. Activity of paclitaxel as second-line chemotherapy in endometrial carcinoma: A GOG study. Gynecol Oncol 2003; 88: 277-281.
19. Fleming GF, Filiaci VL, Bentley RC et al. Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: A Gynecologic Oncology Group study. Ann Oncol 2004; 15: 1173-1178.
20. Fleming G, Brunetto V, Cella D et al. Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial cancer: A GOG study. J Clin Oncol 2004; 11: 2159-2166.
21. McMeekin DS, Filiaci V, Thigpen T et al. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trial: A GOG study. Gynecol Oncol 2007; 106: 16-22.
22. McGuire WP, Hoskins WJ, Brady M et al. Cyclophosphamide and cisplatin compared to paclitaxel and cisplatin in patients with stage III-IV ovarian cancer. N Engl J Med 1996; 334: 1-6.
23. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III-IV ovarian cancer: A GOG study. J Clin Oncol 2000; 18: 106-115.
24. Landrum LM, Moore KN, Myers TN et al. Stage IB endometrial cancer: Does applying an ovarian cancer treatment paradigm result in similar outcomes? A case-control study. Gynecol Oncol 2009; 112: 337-341.
25. Dizon DS, Blessing JA, McMeekin DS et al. Phase II trial of ixabepilone as second-line treatment in advanced endometrial cancer: GOG trial 129-P. J Clin Oncol 2009; 27: 3104-3108.
26. Moore KN, Tian C, McMeekin S et al. Progression-free interval following first-line chemotherapy is associated with survival following second-line chemotherapy in advanced and recurrent endometrial cancer: A GOG ancillary data analysis. Gynecol Oncol 2009; 112 (Suppl): S35 (Abstr 65).
27. Bookman MA, Brady MF, McGuire W et al. Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: A phase III trial of the Gynecologic Cancer InterGroup. J Clin Oncol 2009; 27: 1419-1425.
28. Aghajanian C, Sill MW, Darcy K et al. A phase II evaluation of bevacizumab in the treatment of recurrent or persistent endometrial cancer: A GOG study. J Clin Oncol 2009; 27 (Suppl): 15s (Abstr 5531).